Pureos Bioventures invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs and drug formats. We strive to impact patients’ lives by advancing innovative treatments for severe diseases. Pureos is represented on our board by Dominik Escher, PhD and Anne Grahl, PhD.

+ND Capital invests in disruptive technologies across the life, physical, and data sciences. Our core belief is that scientific disciplines will continue to converge, and that some of the biggest breakthroughs will be based on this convergence. +ND Capital is represented on our board by Kostas Kaloulis, PhD.

Korea Investment Partners is Asia’s Leading Venture Capital and Private Equity House. From early stage ventures to growth stage companies, KIP’s investments deliver a unified goal to create value by forging strong relationships integral to building business across different industries.